Patent Protection vs Public Health: A Critical Study of Pharmaceutical Patents in India

The pharmaceutical industry plays a crucial role in protecting public health through the development of innovative medicines and healthcare technologies. Patent protection is considered an important mechanism for encouraging pharmaceutical research and investment by granting exclusive rights to inventors for a limited period. However, strong patent protection may also create barriers to affordable healthcare by increasing the prices of life-saving medicines and restricting access to essential drugs. Developing countries such as India face significant challenges in balancing intellectual property rights with the constitutional obligation to ensure public health and affordable medical treatment. India has emerged as one of the largest producers of generic medicines in the world and is often referred to as the “pharmacy of the developing world.” At the same time, India is also required to comply with international intellectual property obligations under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). This has created continuous tension between pharmaceutical patent protection and public health interests. This research paper critically examines the legal framework governing pharmaceutical patents in India and analyses the impact of patent protection on access to medicines and public health. The study evaluates important provisions of the Patents Act, 1970, including Section 3(d) and compulsory licensing mechanisms. It also discusses major judicial decisions such as Novartis AG v. Union of India and Bayer Corporation v. Natco Pharma Ltd. which significantly shaped Indian pharmaceutical patent jurisprudence. The paper concludes that India has attempted to maintain a balanced approach by protecting pharmaceutical innovation while safeguarding affordable access to medicines. However, stronger policy measures and effective implementation are still required to ensure that patent protection does not compromise public health and social welfare.